VERIX

Compare peptides

Put two entries side by side — evidence, mechanism, risks, and community claims.

Cagrilintide

Clinical
Research chemical
Summary
Long-acting amylin analog studied alone and with semaglutide (CagriSema) for obesity.
Categories
Metabolic & Body Comp
Mechanism
Amylin receptor agonism → satiety, reduced food intake, delayed gastric emptying.
Half-life
Long-acting (weekly-style regimens in trials)
Routes
Subcutaneous injection
Legal / access
Investigational; not a standard approved monotherapy for consumer use.
Key risks
  • Nausea
  • GI effects
  • Amylin-class tolerability issues
Common claims
  • Additive appetite control with GLP-1s
  • Next pipeline stack
Select peptide B